Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.61 |
| ▸ | NT5E | P21589 | 13/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19974379 | 1.00 | ADORA3 (0.61) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL19987362 | 0.82 | ADORA3 (0.53) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL25090698 | 0.81 | ADORA3 (0.60) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL19366689 | 0.81 | ADORA3 (0.60) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL19987331 | 0.80 | ADORA3 (0.59) | ADORA3ADORA2ANT5EADORA1 | |
| SCHEMBL19974382 | 0.80 | ADORA3 (0.59) | ADORA3ADORA2ANT5EADORA1 | |
| SCHEMBL19987170 | 0.79 | NT5E (0.53) | ADORA3ADORA2ANT5E | |
| SCHEMBL19366658 | 0.79 | NT5E (0.75) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL19974374 | 0.78 | ADORA3 (0.43) | ADORA3ADORA2ANT5EADORA1ADORA2B | |
| SCHEMBL21511191 | 0.78 | ADORA3 (0.43) | ADORA3ADORA2ANT5EADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2019-10-24 | — | — | US | disclosed |
| WO-2018049535-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | LCB PHARMA INC. (CA) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322693-A1 | NUCLEOSIDE ANALOGUES AND METHODS OF USE THEREOF | PNP, TYMP, MTAP | ADORA3 156/4885ADORA2A 146/4885NT5E 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.